02-13-2021, 04:06 PM
(This post was last modified: 02-13-2021, 04:13 PM by Mystic Wanderer.)
Apparently MERCK has decided that therapeutics would be the best candidate for development compared to a vaccine. Have they determined it's better to just get the virus and develop antibodies than taking a vaccine?
Wonder if this has anything to do with all the deaths that took place after people took their poison?
Maybe it was too many people refusing the vaccine that it made it too expensive to make?
I would feel much better taking a therapeutic from Big Pharma than a shot, but I prefer neither.
READ MORE
Wonder if this has anything to do with all the deaths that took place after people took their poison?
Maybe it was too many people refusing the vaccine that it made it too expensive to make?
Quote:KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.
This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.
Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio.
I would feel much better taking a therapeutic from Big Pharma than a shot, but I prefer neither.
Quote:Merck and its collaborators plan to submit the results of the Phase 1 studies for V590 and V591 for publication in a peer-reviewed journal. In addition to advancing the development and production of MK-7110 and MK-4482, Merck will continue to conduct SARS-CoV-2/COVID-19 research. Merck will also continue to evaluate the potential of the measles-virus vector and vesicular stomatitis virus vector-based platforms and pursue broader pandemic-response capabilities. The COVID-19 pandemic underscores the need for our company and our industry to continue to invest in research to address threats to health security.
READ MORE
